S
Shouta Iwadou
Researcher at Okayama University
Publications - 14
Citations - 336
Shouta Iwadou is an academic researcher from Okayama University. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 7, co-authored 14 publications receiving 234 citations.
Papers
More filters
Journal ArticleDOI
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Masatoshi Kudo,Kazuomi Ueshima,Osamu Yokosuka,Sadahisa Ogasawara,Shuntaro Obi,Namiki Izumi,Hiroshi Aikata,Hiroaki Nagano,Etsuro Hatano,Yutaka Sasaki,Keisuke Hino,Takashi Kumada,Kazuhide Yamamoto,Yasuharu Imai,Shouta Iwadou,Chikara Ogawa,Takuji Okusaka,Fumihiko Kanai,Kohei Akazawa,Kenichi Yoshimura,Philip J. Johnson,Yasuaki Arai +21 more
TL;DR: Addition of hepatic arterial infusion chemotherapy to sorafenib did not significantly improve overall survival in patients with advanced, unresectable hepatocellular carcinoma.
Journal ArticleDOI
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
Koji Miyahara,Kazuhiro Nouso,Yuuki Morimoto,Yasuto Takeuchi,Hiroaki Hagihara,Kenji Kuwaki,Hideki Onishi,Fusao Ikeda,Yasuhiro Miyake,Shinichiro Nakamura,Hidenori Shiraha,Akinobu Takaki,Masao Honda,Shuichi Kaneko,Toshiki Sato,S Sato,Shuntaro Obi,Shouta Iwadou,Yoshiyuki Kobayashi,Kouichi Takaguchi,Kazuya Kariyama,Yoshitaka Takuma,Hisashi Takabatake,Kazuhide Yamamoto +23 more
TL;DR: High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.
Journal ArticleDOI
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.
Koji Miyahara,Kazuhiro Nouso,Yuki Morimoto,Yasuto Takeuchi,Hiroaki Hagihara,Kenji Kuwaki,Hideki Onishi,Fusao Ikeda,Yasuhiro Miyake,Shinichiro Nakamura,Hidenori Shiraha,Akinobu Takaki,Shouta Iwadou,Yoshiyuki Kobayashi,Koichi Takaguchi,Yoshitaka Takuma,Hiroyuki Takabatake,Kohsaku Sakaguchi,Kazuhide Yamamoto +18 more
TL;DR: It is investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival.
Journal ArticleDOI
Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma
Masatoshi Kudo,Kazuomi Ueshima,Osamu Yokosuka,Shuntaro Obi,Namiki Izumi,Hiroshi Aikata,Hiroaki Nagano,Etsuro Hatano,Yutaka Sasaki,Kunihiko Hino,Takashi Kumada,Kazuhide Yamamoto,Yasuharu Imai,Shouta Iwadou,Chikara Ogawa,Takuji Okusaka,Y. Arai,Fumihiko Kanai,Kohei Akazawa +18 more
Journal ArticleDOI
Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma
Shouta Iwadou,Kazuhiro Nouso,Kenji Kuwaki,Yoshiyuki Kobayashi,Shinichiro Nakamura,Hironori Tanaka,Kenji Miyoshi,Hideki Ohnishi,Yasuhiro Miyake,Hidenori Shiraha,Yoshiaki Iwasaki,Yasushi Shiratori,Kazuhide Yamamoto +12 more
TL;DR: The aim of this study is to evaluate the predisposing factors after treatments for hepatocellular carcinoma recurrence by analyzing factors analysed only at the initial treatment stage and those analysed during follow-up.